The Pro Medicus Ltd (ASX: PME) share price is in focus after addressing speculation of a potential data breach, confirming no client or patient data was accessed and no financial loss occurred.
Image Source: Getty Images
What did Pro Medicus report?
- Investigated unauthorised access of a single company email inbox in July 2025
- No client systems or patient data were accessed
- No Pro Medicus products, systems, or databases were affected
- No operational impact or financial loss resulted from the incident
- Potential exposure of personal data for approximately 100 current and former employees
- All impacted individuals have been notified
What else do investors need to know?
The company confirmed the cybersecurity incident was isolated to a single mailbox and was quickly contained with the help of external experts. There is no evidence that any commercially sensitive or material information was accessed during the breach.
Pro Medicus has informed all applicable government authorities as required by law, and all directly affected employees were promptly notified about the possible personal data exposure.
What's next for Pro Medicus?
Pro Medicus states that its systems and client information remain secure. The company continues to review its cybersecurity practices and is committed to protecting data in line with industry best practice.
There is no expectation of financial or operational impact, with Pro Medicus focusing on its ongoing delivery of medical imaging software solutions and services worldwide.
Pro Medicus share price snapshot
Over the past 12 months, Pro Medicus shares have declined 3%, trailing the S&P/ASX 200 Index (ASX: XJO) which has risen 2% over the same period.
